Skip to main content
Top
Published in: Infection 3/2013

Open Access 01-06-2013 | Clinical and Epidemiological Study

Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project)

Authors: M. T. Montagna, G. Caggiano, G. Lovero, O. De Giglio, C. Coretti, T. Cuna, R. Iatta, M. Giglio, L. Dalfino, F. Bruno, F. Puntillo

Published in: Infection | Issue 3/2013

Login to get access

Abstract

Purpose

The aims of this study are to evaluate the epidemiology of invasive fungal infections (IFIs) in patients admitted to an intensive care unit (ICU) in Southern Italy and the in vitro antifungal susceptibility of isolates.

Methods

A surveillance program was implemented in 18 ICUs. IFI cases were recorded using a standardized form.

Results

A total of 105 episodes of IFIs occurred in 5,561 patients during the 18-month study. The main infections were caused by yeasts, more than filamentous fungi (overall incidence of 16.5 cases per 1,000 admissions and 2.3 cases per 1,000 admissions, respectively). The overall crude mortality rate was high (42.8 %), particularly for mold infections (61.5 %). All yeast infections were Candida bloodstream infections. Over half (59.8 %) were caused by Candida non-albicans, with C. parapsilosis being the most common (61.8 %). In the multivariate model, trauma admission diagnosis, prolonged stay in the ICU, and parenteral nutrition were independently associated with candidemia due to C. parapsilosis [odds ratio (OR) 3.5, (1.8–5.2); OR 3.5, (1.02–3.5); OR 3.6, (1.28–6.99), respectively]. Among mold infections, 12 patients suffered from invasive pulmonary aspergillosis, with Aspergillus fumigatus as the predominant pathogen (41.7 %). One case of brain scedosporiosis was identified. Overall, azoles and echinocandins resistance was uncommon.

Conclusions

Candida non-albicans species are the most frequent cause of candidemia in ICU patients. Mold infections are associated with a high mortality rate. This study confirms the importance of the epidemiological surveillance on IFIs in the ICU setting for documenting species distribution and antimicrobial susceptibility patterns to guide therapeutic choices.
Literature
1.
go back to reference Bougnoux ME, Kac G, Aegerter P, et al. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med. 2008;34:292–9.PubMedCrossRef Bougnoux ME, Kac G, Aegerter P, et al. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med. 2008;34:292–9.PubMedCrossRef
2.
go back to reference Dimopoulos G, Ntziora F, Rachiotis G, et al. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg. 2008;106:523–9.PubMedCrossRef Dimopoulos G, Ntziora F, Rachiotis G, et al. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg. 2008;106:523–9.PubMedCrossRef
3.
go back to reference Glöckner A, Karthaus M. Current aspects of invasive candidiasis and aspergillosis in adult intensive care patients. Mycoses. 2011;54:420–33.PubMedCrossRef Glöckner A, Karthaus M. Current aspects of invasive candidiasis and aspergillosis in adult intensive care patients. Mycoses. 2011;54:420–33.PubMedCrossRef
4.
go back to reference Chow JK, Golan Y, Ruthazer R, et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis. 2008;46:1206–13.PubMedCrossRef Chow JK, Golan Y, Ruthazer R, et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis. 2008;46:1206–13.PubMedCrossRef
5.
go back to reference Leroy O, Gangneux JP, Montravers P, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med. 2009;37:1612–8.PubMedCrossRef Leroy O, Gangneux JP, Montravers P, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med. 2009;37:1612–8.PubMedCrossRef
6.
go back to reference Caggiano G, Iatta R, Laneve A, et al. Observational study on candidaemia at a university hospital in southern Italy from 1998 to 2004. Mycoses. 2008;51:123–8.PubMedCrossRef Caggiano G, Iatta R, Laneve A, et al. Observational study on candidaemia at a university hospital in southern Italy from 1998 to 2004. Mycoses. 2008;51:123–8.PubMedCrossRef
7.
go back to reference Horasan ES, Ersöz G, Göksu M, et al. Increase in Candida parapsilosis fungemia in critical care units: a 6-years study. Mycopathologia. 2010;170:263–8.PubMedCrossRef Horasan ES, Ersöz G, Göksu M, et al. Increase in Candida parapsilosis fungemia in critical care units: a 6-years study. Mycopathologia. 2010;170:263–8.PubMedCrossRef
8.
go back to reference Pratikaki M, Platsouka E, Sotiropoulou C, et al. Epidemiology, risk factors for and outcome of candidaemia among non-neutropenic patients in a Greek intensive care unit. Mycoses. 2011;54:154–61.PubMedCrossRef Pratikaki M, Platsouka E, Sotiropoulou C, et al. Epidemiology, risk factors for and outcome of candidaemia among non-neutropenic patients in a Greek intensive care unit. Mycoses. 2011;54:154–61.PubMedCrossRef
9.
go back to reference Meersseman W, Van Wijngaerden E. Invasive aspergillosis in the ICU: an emerging disease. Intensive Care Med. 2007;33:1679–81.PubMedCrossRef Meersseman W, Van Wijngaerden E. Invasive aspergillosis in the ICU: an emerging disease. Intensive Care Med. 2007;33:1679–81.PubMedCrossRef
10.
go back to reference Russo A, Falcone M, Vena A, et al. Invasive pulmonary aspergillosis in non-neutropenic patients: analysis of a 14-month prospective clinical experience. J Chemother. 2011;23:290–4.PubMed Russo A, Falcone M, Vena A, et al. Invasive pulmonary aspergillosis in non-neutropenic patients: analysis of a 14-month prospective clinical experience. J Chemother. 2011;23:290–4.PubMed
11.
go back to reference Tortorano AM, Dho G, Prigitano A, et al. Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006–2008). Mycoses. 2012;55:73–9.PubMedCrossRef Tortorano AM, Dho G, Prigitano A, et al. Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006–2008). Mycoses. 2012;55:73–9.PubMedCrossRef
12.
go back to reference Montagna MT, Lovero G, De Giglio O, et al. Invasive fungal infections in neonatal intensive care units of Southern Italy: a multicentre regional active surveillance (AURORA project). J Prev Med Hyg. 2010;51:125–30.PubMed Montagna MT, Lovero G, De Giglio O, et al. Invasive fungal infections in neonatal intensive care units of Southern Italy: a multicentre regional active surveillance (AURORA project). J Prev Med Hyg. 2010;51:125–30.PubMed
13.
go back to reference Montagna MT, De Giglio O, Napoli C, et al. Invasive fungal infections in patients with hematologic malignancies (AURORA project): lights and shadows during 18-months surveillance. Int J Mol Sci. 2012;13:774–87.PubMedCrossRef Montagna MT, De Giglio O, Napoli C, et al. Invasive fungal infections in patients with hematologic malignancies (AURORA project): lights and shadows during 18-months surveillance. Int J Mol Sci. 2012;13:774–87.PubMedCrossRef
14.
go back to reference Pittet D, Monod M, Suter PM, et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220:751–8.PubMedCrossRef Pittet D, Monod M, Suter PM, et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220:751–8.PubMedCrossRef
15.
go back to reference Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–10.PubMedCrossRef Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–10.PubMedCrossRef
16.
go back to reference de Hoog GS, Guarro J, Gené J, Figueras MJ. Atlas of clinical fungi. 3rd ed. The Netherlands: Centraalbureau voor Schimmelcultures (CBS); 2009. de Hoog GS, Guarro J, Gené J, Figueras MJ. Atlas of clinical fungi. 3rd ed. The Netherlands: Centraalbureau voor Schimmelcultures (CBS); 2009.
17.
go back to reference Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; Approved standard, 2nd ed. CLSI document M38-A2. Wayne: CLSI; 2008. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; Approved standard, 2nd ed. CLSI document M38-A2. Wayne: CLSI; 2008.
18.
go back to reference Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard, 3rd ed. CLSI document M27-A3. Wayne: CLSI; 2008. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard, 3rd ed. CLSI document M27-A3. Wayne: CLSI; 2008.
19.
go back to reference Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med. 2012;125:S3–13.PubMedCrossRef Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med. 2012;125:S3–13.PubMedCrossRef
20.
go back to reference Pfaller MA, Andes D, Arendrup MC, et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis. 2011;70:330–43.PubMedCrossRef Pfaller MA, Andes D, Arendrup MC, et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis. 2011;70:330–43.PubMedCrossRef
21.
go back to reference Diekema DJ, Messer SA, Boyken LB, et al. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol. 2009;47:3170–7.PubMedCrossRef Diekema DJ, Messer SA, Boyken LB, et al. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol. 2009;47:3170–7.PubMedCrossRef
22.
go back to reference Espinel-Ingroff A, Diekema DJ, Fothergill A, et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol. 2010;48:3251–7.PubMedCrossRef Espinel-Ingroff A, Diekema DJ, Fothergill A, et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol. 2010;48:3251–7.PubMedCrossRef
23.
go back to reference Espinel-Ingroff A, Cuenca-Estrella M, Fothergill A, et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother. 2011;55:5150–4.PubMedCrossRef Espinel-Ingroff A, Cuenca-Estrella M, Fothergill A, et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother. 2011;55:5150–4.PubMedCrossRef
24.
go back to reference Espinel-Ingroff A, Fothergill A, Fuller J, et al. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother. 2011;55:2855–9.PubMedCrossRef Espinel-Ingroff A, Fothergill A, Fuller J, et al. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother. 2011;55:2855–9.PubMedCrossRef
25.
go back to reference Katz MH. Multivariable analysis: a primer for readers of medical research. Ann Intern Med. 2003;138:644–50.PubMedCrossRef Katz MH. Multivariable analysis: a primer for readers of medical research. Ann Intern Med. 2003;138:644–50.PubMedCrossRef
26.
go back to reference Chalmers CM, Bal AM. Management of fungal infections in the intensive care unit: a survey of UK practice. Br J Anaesth. 2011;106:827–31.PubMedCrossRef Chalmers CM, Bal AM. Management of fungal infections in the intensive care unit: a survey of UK practice. Br J Anaesth. 2011;106:827–31.PubMedCrossRef
27.
go back to reference Jordà-Marcos R, Alvarez-Lerma F, Jurado M, et al. Risk factors for candidaemia in critically ill patients: a prospective surveillance study. Mycoses. 2007;50:302–10.PubMedCrossRef Jordà-Marcos R, Alvarez-Lerma F, Jurado M, et al. Risk factors for candidaemia in critically ill patients: a prospective surveillance study. Mycoses. 2007;50:302–10.PubMedCrossRef
28.
go back to reference Bassetti M, Taramasso L, Nicco E, et al. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One. 2011;6:e24198.PubMedCrossRef Bassetti M, Taramasso L, Nicco E, et al. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One. 2011;6:e24198.PubMedCrossRef
29.
go back to reference Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:1–45.PubMedCrossRef Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:1–45.PubMedCrossRef
30.
go back to reference Nucci M, Queiroz-Telles F, Tobón AM, et al. Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis. 2010;51:561–70.PubMedCrossRef Nucci M, Queiroz-Telles F, Tobón AM, et al. Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis. 2010;51:561–70.PubMedCrossRef
31.
go back to reference Trofa D, Gácser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev. 2008;21:606–25.PubMedCrossRef Trofa D, Gácser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev. 2008;21:606–25.PubMedCrossRef
32.
go back to reference Negri M, Silva S, Henriques M, Oliveira R. Insights into Candida tropicalis nosocomial infections and virulence factors. Eur J Clin Microbiol Infect Dis. 2012;31:1399–412.PubMedCrossRef Negri M, Silva S, Henriques M, Oliveira R. Insights into Candida tropicalis nosocomial infections and virulence factors. Eur J Clin Microbiol Infect Dis. 2012;31:1399–412.PubMedCrossRef
33.
go back to reference Bassetti M, Ansaldi F, Nicolini L, et al. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother. 2009;64:625–9.PubMedCrossRef Bassetti M, Ansaldi F, Nicolini L, et al. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother. 2009;64:625–9.PubMedCrossRef
34.
go back to reference Lin MY, Carmeli Y, Zumsteg J, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case–case–control study. Antimicrob Agents Chemother. 2005;49:4555–60.PubMedCrossRef Lin MY, Carmeli Y, Zumsteg J, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case–case–control study. Antimicrob Agents Chemother. 2005;49:4555–60.PubMedCrossRef
35.
go back to reference Pfaller MA, Messer SA, Moet GJ, et al. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009). Int J Antimicrob Agents. 2011;38:65–9.PubMedCrossRef Pfaller MA, Messer SA, Moet GJ, et al. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009). Int J Antimicrob Agents. 2011;38:65–9.PubMedCrossRef
36.
go back to reference Tortorano AM, Prigitano A, Dho G, et al. Antifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian intensive care units. J Med Microbiol. 2012;61:389–93.PubMedCrossRef Tortorano AM, Prigitano A, Dho G, et al. Antifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian intensive care units. J Med Microbiol. 2012;61:389–93.PubMedCrossRef
37.
go back to reference Lyon GM, Karatela S, Sunay S, et al. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol. 2010;48:1270–5.PubMedCrossRef Lyon GM, Karatela S, Sunay S, et al. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol. 2010;48:1270–5.PubMedCrossRef
38.
go back to reference Vandewoude KH, Blot SI, Depuydt P, et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care. 2006;10:R31.PubMedCrossRef Vandewoude KH, Blot SI, Depuydt P, et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care. 2006;10:R31.PubMedCrossRef
39.
go back to reference Vandewoude KH, Blot SI, Benoit D, et al. Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect. 2004;56:269–76.PubMedCrossRef Vandewoude KH, Blot SI, Benoit D, et al. Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect. 2004;56:269–76.PubMedCrossRef
40.
go back to reference Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J. 2007;30:782–800.PubMedCrossRef Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J. 2007;30:782–800.PubMedCrossRef
41.
go back to reference Maris C, Martin B, Creteur J, et al. Comparison of clinical and post-mortem findings in intensive care unit patients. Virchows Arch. 2007;450:329–33.PubMedCrossRef Maris C, Martin B, Creteur J, et al. Comparison of clinical and post-mortem findings in intensive care unit patients. Virchows Arch. 2007;450:329–33.PubMedCrossRef
Metadata
Title
Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project)
Authors
M. T. Montagna
G. Caggiano
G. Lovero
O. De Giglio
C. Coretti
T. Cuna
R. Iatta
M. Giglio
L. Dalfino
F. Bruno
F. Puntillo
Publication date
01-06-2013
Publisher
Springer-Verlag
Published in
Infection / Issue 3/2013
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-013-0432-0

Other articles of this Issue 3/2013

Infection 3/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.